Anthracyclines just as doxorubicin are the initial treatment of choice for TNBC. Although doxorubicin has reduced breast cancer mortality significantly, it is linked with a dose-dependent cumulative and
Castle Creek is a portfolio company of Paragon Biosciences, which took part in this preferred stock financing. This financing round saw continued support from Fidelity Management & Research
Biliary tract cancer, which is also called as cholangiocarcinoma, is an extremely rare and hard to treat cancer. It impacts more than 2,000 people in the UK annually
Zavegepant nasal spray is claimed to be the only small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in an intranasal formulation for the acute treatment of migraine in
The positive opinion for use of Cosentyx either alone or in combination with methotrexate has been given for the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA)
Proceeds from the financing round will be used by the company to advance Inceptor Bio’s CAR-T lead programme to a Phase I clinical trial as well as continue
This round was led by founding investors Syncona and Mass General Brigham Ventures. With this new funding round, SwanBio has so far raised $133m. SwanBio chair and chief
Grupo Somar is an integrated pharmaceutical company with focus on developing, manufacturing, and marketing branded generic, private label and OTC products aimed at the private market and providing
This multi-year deal builds on the ongoing collaboration with AstraZeneca announced in June last year, to include the development of small molecule inhibitors targeting a second cancer-related epigenetic
Statera Biopharma president and CEO Michael K Handley said: “The strategic partnership with Lay Sciences has the potential to produce near term revenue. “The agreement allows Statera the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.